Устекинумаб — новый препарат для лечения псориаза и псориатического артрита

1. <div><p>Молочнов В.А., Бадокин В.В., Альбанова В.И. и др. Псориаз и псориатический артрит. М.: Tоварищество научных изданий КМК. Авторская академия, 2007.</p><p>Van der Kerkhof P.C.M., SchaLkwijk J. Psoriasis. In: Bolognia J.L., Jorizzo J.L., Rapini R.P., eds. Dermatology. 2nd ed. Spain: Mosby, 2008:115-36.</p><p>Boumpas D.T., IlLei G.G., Tassiulas I.O. Psoriatic arthritis. In: Klippel J.H., Crofford L.J., Stone J.H., Weyand C.M., eds. Primer on the rheumatic diseases. 12th ed. Atlanta, Georgia: Arthritis Foundation, 2001:233-8.</p><p>Saraceno R., Mannheimer R., Chimenti S. Regional distribution of psoriasis in Italy. J Eur Acad Dermatol Venereol 2008;22:324-9.</p><p>Gelfand J.M., Weinstein R., Porter S.B. et al. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol 2005;141:1537-41.</p><p>Ferrandiz C., Bordas X., Garcia-Patos V. et al. Prevalence of psoriasis in Spain (Epiderma Project: phase I). J Eur Acad Dermatol Venereol 2001;15:20-3.</p><p>Fredriksson T., Pettersson U. Severe psoriasis oral therapy with a new retinoid. Dermatologica 1978;157:238-44.</p><p>Shbeeb M., Uramoto K.M., Gibson L.E. et al. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol 2000;27:1247-50.</p><p>Leonard D.G., O’Duffy D.J., Rogers III R.S. Prospective analysis of psoriatic arthritis in patients hospitalized for psoriasis. Mayo Clin Proc 1978;53:511-8.</p><p>Gladman D.D., Shuckett R., Russell M.L. et al. Psoriatic arthritis (PSA) an analysis of 220 patients. Q J Med. 1987;62:127-41.</p><p>Бадокин В.В. Псориатический артрит. В кн.: Ревматология. Клинические лекции. Под ред. В.В. Бадокина. М.: Литтерра, 2012; 151-82.</p><p>Torre-Alonso J.C., Rodriguez Perez A., Arribas Castrillo J.M. et al. Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 Patients. Br J Rheumatol 1991;30:245-50.</p><p>Sokoll K.B., Helliwell P.S. Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol 2001;28:1842-6.</p><p>Wong K., Gladman D.D., Husted J. et al. Mortality studies in psoriatic arthritis. Results from a single outpatient clinic. I: Causes and risk of death. Arthr Rheum 1997;40:1868-72.</p><p>Gladman D.D., Farewell V.T., Wong K. et al. Mortality studies in psoriatic arthritis. Results from a single outpatient center. II. Prognostic indicators for death. Arthr Rheum 1998;41:1103-10.</p><p>Mease PJ., Goffe B.S., Metz J. et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-90.</p><p>Mease PJ., Kivitz A.J., Burch F.X. et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthr Rheum 2004;50:2264-72.</p><p>Румянцева О.А., Бочкова А.Г., Логинова Е.Ю. и др. Исследование эффективности, безопасности и переносимости инфликсимаба у больных анкилозирующим спондилитом (предварительные результаты). Науч-практич ревматол 2006;4:11-9.</p><p>Муравьев Ю.В., Дорошкевич И.А. Что делать, если в период лечения ингибиторами фактора некроза опухоли а возник псориаз? Науч-практич ревматол 2011;5:89-91.</p><p>Borras-Blasco J., Navarro-Ruiz A., Borras C. et al. Adverse cuta neous reactions induced by TNF-alpha antagonist therapy. South Med J 2009;102:1133-40.</p><p>Kary S., Worm M., Audring H. et al. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor α antagonists. Ann Rheum Dis 2006;65:405-7.</p><p>Thurber M., Feasel A., Stroehlein J. et al. Pustular psoriasis induced by infliximab. J Drugs Dermatol 2004;3:439-40.</p><p>Nickoloff B.J., Qin J.Z., Nestle F.O. Immunopathogenesis of psoriasis. Clin Rev Allergy Immunol 2007;33:45-56.</p><p>Ghoreschi K., Weigert C., Röcken M. Immunopathogenesis and role of T cells in psoriasis. Clin Dermatol 2007;25:574-80.</p><p>Nestle F.O. Psoriasis. Curr Dir Autoimmun 2008;10:65-75.</p><p>Torti D.C., Feldman S.R. Interleukin-12, interleukin-23, and psoriasis: current prospects. J Am Acad Dermatol 2007;57:1059-68.</p><p>Van Beelen A.J., Teunissen M.B., Kapsenberg M.L. et al. Interleukin-17 in inflammatory skin disorders. Curr Opin Allergy Clin Immunol 2007;7:374-81.</p><p>Ribbens C. Andre B., Kaye O. et al. Increased synovial fluid levels of interleukin-12, sCD25 and sTNF-RII/sTNF-RI ratio delineate a cytokine pattern characteristic of immune arthropathies. Eur Cytokine Netw 2000;11:669-76.</p><p>Ritchlin C., Haas-Smith S.A., Hicks D. et al. Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998;25:1544-52.</p><p>Peeva E., Fishman A.D., Goddard G. et al. Rheumatoid arthritis exacerbation caused by exogenous Interleukin-12. Arthr Rheum 2000;43:461-3.</p><p>Rahman P., Inman R.D., Maksymowych W.P et al. Association of interleukin-23 receptor variants with psoriatic arthritis. J Rheumatol 2009;36:137-40.</p><p>Hunter C.A. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol 2005;5:521-31.</p><p>Presky D.H., Yang H., Minetti L.J. et al. A functional interleukin-12 receptor complex is composed of two beta-type cytokine receptor subunits. Proc Natl Acad Sci USA 1996;93:14002-7.</p><p>Parham C., Chirica M., Timans J. et al. A receptor for the het-erodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol 2002;168:5699-708.</p><p>Aggarwal S., Ghilardi N., Xie M.H. et al. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003;278:1910-4.</p><p>Teunissen M.B.M., Koomen C.W., de Waal Malefit R. et al. Interleukin-17 and interferon-synergize in enhancement of proin-flammatory cytokine production by human keratinocytes. J Invest Dermatol 1998;111:645-9.</p><p>Hong K., Chu A., Ludviksson B.R. et al. IL-12, independently of IFN-gamma, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder. J Immunol 1999;162:7480-91.</p><p>Kopp T., Kieffer J.D., Rot A. et al. Inflammatory skin disease in K14/p40 transgenic mice: evidence for interleukin-12-like activities of p40. J Invest Dermatol 2001;117:618-26.</p><p>Kopp T., Lenz P., Bello-Fernandez C. et al. IL-23 production by cosecretion of endogenous p19 and transgenic p40 in keratin 14/p40 transgenic mice: evidence for enhanced cutaneous immunity. J Immunol 2003;170:5438-44.</p><p>Kauffman C.L., Aria N., Toichi E. et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol 2004;123:1037-44.</p><p>Krueger G.G., Langley R.G., Leonardi C. et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007;356:580-92.</p><p>Cargill M., Schrodi S.J., Chang M. et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007;80:273-90.</p><p>Duerr R.H., Taylor K.D., Brant S.R. et al. A genome-wide association study identifies IL23R as an infiammatory bowel disease gene. Science 2006;314:1461-63.</p><p>Capon F., Di Meglio P., Szaub J. et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet 2007;122:201—6.</p><p>Piskin G., Sylva-Steenland R.M.R., Bos J.D. et al. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol 2006;176:1908-15.</p><p>Torti D.C., Feldman S.R. Interleukin-12, interleukin-23, and psoriasis: current prospects. J Am Acad Dermatol 2007;57:1059-68.</p><p>Kimball A., Gordon K.B., Langley R.G. et al. Safety and efficacy of ABT-874, a fully human interleukin-12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol 2008;144:200-7.</p><p>Bennet J.C. Approach to the patient with immune disease. In: Goldman L., Bennet J.C., eds. Cecil Textbook of Medicine. 21st ed. Philadelphia, PA: W.B. Saunders Company, 2000:1423—9.</p><p>National Institute for Health and Clinical Excellence (NICE). Ustekinumab for the treatment of adults with moderate to severe psoriasis. NICE Technology Appraisal Guidance 180. London, UK: NICE, 2009.</p><p>Kauffman C.L., Aria N., Toichi E. et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12p40 antibody in subjects with plaque psoriasis. J Invest Dermatol 2004;123:1037-44.</p><p>Gottlieb A.B., Cooper K.D., McCormick T.S. et al. A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. Curr Med Res Opin 2007;23:1081—92.</p><p>Krueger G.G., Langley R.G., Leonardi C. et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007;356:580-92.</p><p>Gottlieb A., Menter A., Mendelsohn A. et al. Ustekinumab, a human interleukin-12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009;373:633—40.</p><p>Sandborn WJ., Feagan B.G., Fedorak R.N. et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology 2008;135:1130-41.</p><p>Segal B.M., Constantinescu C.S., Raychaudhuri A. et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 2008;7:796.</p><p>Buttmann M. Treating multiple sclerosis with monoclonal antibodies: a 2010 update. Expert Rev Neurother 2010;10:791-809.</p><p>Leonardi C.L., Kimball A.B., Papp K.A. et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371:1665—74.</p><p>Finlay A.Y., Khan G.K. Dermatology life quality index (DLQI) — a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-6.</p><p>Papp K.A., Langley R.G., Lebwohl M. et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371:1675—84.</p><p>Griffiths C.E.M., Strober B.E., van de Kerkhof P. et al. ACCEPT Study Group. Comparison of ustekinumab and etanercept for moderate to severe psoriasis. N Engl J Med 2010;362:118-28.</p><p>Santos-Juanes J., Coto-Segura P., Mas-Vidal A., Galache Osuna C. Ustekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumour necrosis factor therapies. Br J Dermatol 2010;162:1144-6.</p><p>Igarashi I., Keto T., Kato M. et al. A randomized, double-blind, placebo-controlled study of ustekinumab in Japanese patients with moderate to severe plaque psoriasis [abstract]. Poster P038 presented at the Congress of the Psoriasis International Network; July 1—4, 2010.</p><p>Youn J.I., Tsai T.F., Song M. et al. Efficacy and safety of ustekinumab for the treatment of moderate to severe psoriasis: results of a phase 3 trial in Taiwanese and Korean patients [abstract]. Poster presentation at the 1st Eastern Asia Dermatology Congress, September 30 — October 3, 2010; Poster CS06—03.</p><p>Filipe-Santos O., Bustamante J., Chapgier A. et al. Inborn errors of IL-12/23 and IFN-gamma-mediated immunity: molecular, cellular, and clinical features. Semin Immunol 2006;18:347-61.</p><p>Tsai T.F., Ho V., Song M. et al. The safety of ustekinumab treatment in patients with moderate to severe psoriasis and latent tuberculosis infection. Br J Dermatol 2012; Jul 14 [Epub. ahead of print].</p><p>Comstock G.W. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 1999;3:847-50.</p><p>Nolan C.M., Goldberg S.V., Buskin S.E. Hepatotoicity associated with isoniazid preventive therapy: a 7-years survey from a public health tuberculosis clinic. JAMA 1999;281:1014-8.</p><p>Reich K., Langley R.G., Lebwohl M. et al. Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol 2011;164:862-72.</p><p>LinV.W., Ringold S., Devine E.B. Comparison of Ustekinumab with other biological agents for the treatment of moderate to severe plaque psoriasis. Arch Dermatol 2012; Oct 15 [Epub. ahead of print].</p><p>Сура М.В., Авксентьева М.В., Омельяновский В.В. и др. Клинико-экономический анализ применения устекинумаба (Стелара) у пациентов с тяжелыми клиническими формами псориаза. Вестн дерматол венерол 2011;3:63-70.</p><p>Menter A., Feldman S.R., Weinstein G.D. et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate to severe plaque psoriasis. J Am Acad Dermatol 2007;56:31.e1—15.</p><p>Menter A., Tyring S.K., Gordon K. et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008;58:106-15.</p><p>Reich K., Nestle F.O., Papp K. et al. Infliximab induction and maintenance therapy for moderate to severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005;366:1367-74.</p><p>Saurat J.H., Stingl G., Dubertret L. et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008;158:558-66.</p><p>Курдина М.И. Новое в системной терапии псориаза. Клин дерматол венерол 2011;5:54-7.</p><p>Croxtall J.D. Spotlight on ustekinumab in moderate to severe plaque psoriasis. Am J Clin Dermatol 2012;13:135-7.</p><p>Garcia-Valladares I., Cuchacovich R., Espinoza L.R. Comparative assessment of biologics in treatment of psoriasis: drug design and clinical effectiveness of ustekinumab. Drug Des Devel Ther 2011;5:41-9.</p></div><br />